MB076

MB076 Structure
MB076 structure
Common Name MB076
CAS Number 2832966-95-5 Molecular Weight 373.18
Density N/A Boiling Point N/A
Molecular Formula C9H12BN7O5S2 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of MB076


MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values < 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility[1].

 Names

Name MB076

 MB076 Biological Activity

Description MB076 is a novel heterocyclic triazole with improved plasma stability. MB076 inhibits seven different Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with Ki values < 1 μM. MB076 acts synergistically in combination with multiple cephalosporins to restore pBCSK(−) susceptibility[1].
Related Catalog
Target

Ki Target: ADC-7, ADC-30, ADC-162, ADC-33, ADC-219, ADC-212[1] Ki: 0.21±0.016 μM (ADC-7), 0.058±0.005μM (ADC-30), 0.79±0.039μM (ADC-162), 0.10±0.004μM (ADC-33), 0.11±0.019 (ADC-219), 0.61±0.038μM (ADC-212)[1]

References

[1]. Rachel A. Powers, et al. Synthesis of a Novel Boronic Acid Transition State Inhibitor, MB076: A Heterocyclic Triazole Effectively Inhibits Acinetobacter-Derived Cephalosporinase Variants with an Expanded-Substrate Spectrum. J Med Chem. 2023 Jul 13; 66(13): 8510–8525.

 Chemical & Physical Properties

Molecular Formula C9H12BN7O5S2
Molecular Weight 373.18
InChIKey JADCONPWNUDUNV-YFKPBYRVSA-N
SMILES Nc1nnc(SCC(=O)NC(Cn2cc(C(=O)O)nn2)B(O)O)s1
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.